How Is Clovis Oncology Inc. (CLVS)’s Price-To-Earnings Ratio?

As of Thursday close, Clovis Oncology Inc.’s (NASDAQ:CLVS) stock was up $0.21, moving up 13.73 percent to $1.74. The average number of shares traded per day over the past five days has been 37,374,980 shares. 3 times new highs have been achieved over the past 5 days, with a $0.7732 gain in that time frame. In the last twenty days, the average volume was 16,651,086, while in the previous 50 days, it was 10,615,760.

Since last month, CLVS stock rose 154.05%. Shares of the company fell to $0.5810 on 06/13/22, the lowest level in the past month. A 52-week high of $6.65 was reached on 04/06/22 after having rallying from a 52-week low of $0.58. Since the beginning of this year, CLVS’s stock price has dropped by -35.79% or -$0.9700, and marked a new high 2 times. However, the stock has declined by -73.83% since its 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Clovis Oncology Inc. (CLVS) last reported insider trading activity 22 days ago on Jun 02. Rolfe Lindsey, the of the company, disposed of 2,650 shares for $0.64 on Jun 02. It resulted in a $1,703 divestment by the insider. Harding Thomas C. sold 218 shares at an average price of $0.64 on Jun 02. The insider now owns 3,225 shares following the transaction. On Jun 02, Harding Thomas C. sold 1,504 shares at $0.64 apiece. The transaction was valued at $966.

Financial Health

In the three months ended March 30, Clovis Oncology Inc.’s quick ratio stood at 1.40, while its current ratio was 1.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 73.40% percent. Based on annual data, CLVS earned $109.93 million in gross profit and brought in $148.76 million in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -67.70%. Return on equity (ROE) for the past 12 months was 101.90%.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. CLVS’s revenue fell -11.09% to $35.97 million during the quarter, while net income inched up to $34.25 million. While analysts expected Clovis Oncology Inc. to report -$0.43 quarterly earnings, the actual figure was -$0.44 per share, beating the consensus estimate by -2.30%. During the quarter, the company generated -$47.88 million in EBITDA. The liabilities of Clovis Oncology Inc. were 754.84 million at the end of its most recent quarter ended March 30, and its total debt was $653.56 million. The value of shareholders’ equity is $143.88 million.

Technical Picture

This quick technical analysis looks at Clovis Oncology Inc.’s (CLVS) price momentum. With a historical volatility rate of 240.10%, the RSI 9-day stood at 79.08% on 23 June.

With respect to its five-day moving average, the current Clovis Oncology Inc. price is up by +79.98% percent or $0.7732. At present, CLVS shares trade +176.15% above its 20-day simple moving average and -9.84% percent below its 100-day simple moving average. However, the stock is currently trading approximately -28.10% below its SMA50 and -62.50% below its SMA200.

Stochastic coefficient K was 58.04% and Stochastic coefficient D was 70.34%, while ATR was 0.3077. Given the Stochastic reading of 63.72% for the 14-day period, the RSI (14) reading has been calculated as 71.29%. As of today, the MACD Oscillator reading stands at 0.5117, while the 14-day reading stands at 0.6522.

Analyst Ratings

Clovis Oncology Inc. downgraded its rating on Clovis Oncology Inc. (NASDAQ: CLVS) to a Neutral in a note to investors on May 06, 2022. The analysts firm previously had a Buy rating on the stock.Clovis Oncology Inc. (CLVS) has been rated Hold by analysts. According to 0 brokerage firms, CLVS is a sell, and 2 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Clovis Oncology Inc. stock as buy, with 0 recommending it as overweight.

With a median target price of $3.00, the current consensus forecast for the stock is $3.00 – $3.00. Based on these forecasts, analysts predict Clovis Oncology Inc. (CLVS) will achieve an average price target of $3.00.


Please enter your comment!
Please enter your name here

Hot Topics

Related Articles




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam